GRAL · GRAIL Inc
United States · RS rating 91 · As of 2026-11-03
| Price | 139.44 USD |
|---|---|
| 1-day change | +4.2% |
| RS rating (overall / 1M / 3M / 12M) | 91 / 36 / 97 / 86 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 56 / 76 / 41 |
| Industry group (rank) | Medical-Research Eqp/Svc (46) |
| EPS growth Q/Q | +0.8% |
| Sales growth Q/Q | +20.4% |
| Distance from 52-week high | +12.3% |
| Market cap (USD) | $2.1B |